CC
FATE icon

Centiva Capital’s Fate Therapeutics FATE Stock Holding History

Centiva Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,885
Closed -$50.6K – 1931
2023
Q3 		$50.6K Sell
23,885
-201
-0.8% -$666 ﹤0.01% 1601
2023
Q2 		$115K Buy
+24,086
New +$133K ﹤0.01% 1436
2021
Q3 		– Sell
-2,821
Closed -$245K – 1377
2021
Q2 		$245K Buy
+2,821
New +$227K 0.01% 1111
2020
Q3 		– Sell
-11,235
Closed -$385K – 750
2020
Q2 		$385K Buy
+11,235
New +$335K 0.02% 351

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Centiva Capital's FATE Position: Q4 2023 in Review

Centiva Capital sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 23,885 shares — an estimated $50.6K sold.

Centiva Capital first reported a position in FATE in Q2 2020 and held it in 4 quarters. The position peaked at $385K in Q2 2020. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Centiva Capital reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 23,885 Fate Therapeutics shares in Q4 2023, an estimated $50.6K.
  • Centiva Capital first reported a position in Fate Therapeutics in Q2 2020 and held it in 4 quarters.
  • Centiva Capital's Fate Therapeutics position peaked at $385K in Q2 2020.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.